Very pleased to announce that Dr. Andrés Pizzorno – Signia Therapeutics’ cofounder and Project Manager – has been invited by the Scientific Committee of the Options for the Control of Influenza X Conference, to be held in Singapore from August 28 to September 1 2019, to give a presentation on “Potential host-targeted therapies for influenza”.
The presentation – on Friday August 30 at 10.30 am – will showcase an update of the current clinical trial landscape in the field and a discussion on the future research directions in order to consolidate the host-targeted anti-influenza agents as an important contribution to our limited therapeutic arsenal, not only as putative standalone therapies but also with special focus on their combinatory potential with current classic virus-targeted inhibitors.
The Options X Conference is the premier global meeting focused on influenza, targeting more than 1,500 participants from across the globe. Visit the ISIRV Options X website (https://2019.isirv.org/) for detailed information.